The single-dose RSV vaccine developed by Pfizer is administered to expectant mothers in the late second-to-third trimester of their pregnancy.
The FDA is reviewing Pfizer's RSV vaccine on an expedited basis and will make a decision on whether to clear the shot by August.
The antibodies triggered by the shot are passed to the fetus, and they protect the infant from RSV after birth.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
1st RSV vaccine could be approved by August, pending FDA reviewThe FDA will decide whether or not to approve an RSV vaccine designed to protect newborns by August 2023.
Read more »
1st RSV vaccine could be approved by August, pending FDA reviewPfizer's vaccine would be the first RSV vaccine given to pregnant people to protect infants. The company said that there were 'no safety concerns' for vaccinated pregnant participants and their newborns during the trial.
Read more »
Pfizer is using AI to help revolutionize the development of life-saving medicationsArtificial intelligence and machine learning are accelerating innovation at every step
Read more »
Health care vaccine mandate remains as some push for an endOne year after it began being enforced nationwide on Feb. 20, 2022, the vaccination requirement affecting an estimated 10 million health care workers is the last remaining major mandate from the U.S.'s sweeping attempt to boost national vaccination rates.
Read more »
Health care vaccine mandate remains as some push for an endThe health care vaccination mandate is scheduled to run until November 2024. but some contend it’s time to stop now.
Read more »
Health care vaccine mandate remains as some push for an endA federal mandate for health care workers to get vaccinated against COVID-19 has been in place nationally for a year.
Read more »